(CercleFinance.com) – Bayer AG today announced the opening of its new Research and Innovation Center at Kendall Square in Boston-Cambridge, Massachusetts (USA), further expanding the company’s footprint in one of the most innovative pharmaceutical research and development sites in the world.
This site of more than 5700 m² required an investment of 140 million dollars. It houses a new precision molecular oncology research center equipped with state-of-the-art laboratories and offices for the development of new targeted cancer therapies for patients.
In addition, the center is also home to a newly created research team that is focused on harnessing chemical biology techniques to further propel the company’s oncology drug development process.
“Our new Bayer Research and Innovation Center in Kendall Square is part of our strategy to be at the forefront of scientific discovery and breakthrough innovation for better patient healthcare,” said Stefan Oelrich, Member of the Board of Directors of Bayer AG and Chairman of Bayer. Pharmaceutical Division. ‘
© 2022 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
